Findings

What do systematic reviews say?

169 questions · 174 findings · 18 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 53 · 30.5%GRADE not reported 13 · 7.5%Very low 23 · 13.2%Low 41 · 23.6%Moderate 34 · 19.5%High 10 · 5.7%

Oral retinoids: alitretinoin 10 mg vs placebo

Secondary: investigator‐rated reduction in severity of TLSSd · people with moderate to severe chronic hand eczema

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 158 participants
Moderate

0.1% triamcinolone acetonide in orabase vs ciclosporin

Physician Global Assessment (Thongprasom score) · People with erosive oral lichen planus

0.1% triamcinolone acetonide in orabase showed no clear difference in physician Global Assessment (Thongprasom score) compared with ciclosporin solution; GRADE not reported.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
MD 0.61 [-0.79, 2.01]
1 study · 11 participants
GRADE not reported

0.1% triamcinolone acetonide in orabase vs ciclosporin

Pain reduction (VAS 0-100) · People with erosive oral lichen planus

0.1% triamcinolone acetonide in orabase led to higher pain reduction (VAS 0-100) compared with ciclosporin solution; GRADE not reported.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
MD 45.17 [8.73, 81.61]
1 study · 11 participants
GRADE not reported

0.1% triamcinolone acetonide in orabase vs ciclosporin

Side effects · People with erosive oral lichen planus

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
Table 3 (Side-effects). Yoke 2006: no significant adverse events; transient burning sensation upon initial application with both treatments.
1 study · 15 participants
GRADE not reported

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

HRQOL RosaQoL · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Proportion of participants with adverse event · Participants with rosacea

Clindamycin phosphate 1.2% + tretinoin 0.025% gel probably leads to higher proportion of participants with adverse event compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
RR 2.45 [1.42, 4.23]
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Physician‐assessed improvement in rosacea severity · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Assessment of erythema or telangiectasia · Participants with rosacea

Clindamycin phosphate 1.2% + tretinoin 0.025% gel showed no clear difference in assessment of erythema or telangiectasia compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
RR 1.71 [0.7, 4.18]
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Lesion count · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Moderate

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Time needed until improvement of the skin lesions · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo

Duration of remission ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream

Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis

It is very uncertain whether triamcinolone acetonide 0.1% cream with occlusive dressing changes proportion of participants cleared or almost cleared ‐ compared with clobetasol cream 0.05% cream (very low certainty).

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
RR 1.2 [0.72, 2]
1 study · 19 participants
Very low

Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream

Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream

Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Very low

Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream

Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Minoxidil vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Topical hair growth stimulants (minoxidil) changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
RR 2.31 [1.34, 3.96]
2 studies · 202 participants
Very low